Bisphosphonates induce apoptosis in human breast cancer cell lines

British Journal of Cancer

Volumn 82, Issue 8, 2000, Pages 1459-1468

  Senaratne, S G ^a   Pirianov, G ^a   Mansi, J L ^a   Arnett, T R ^b   Colston, K W ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Apoptosis; Bisphosphonates; Breast cancer cells

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DNA; EB 1053; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PAMIDRONIC ACID; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

APOPTOSIS; ARTICLE; ASSAY; BREAST CANCER; CANCER CELL CULTURE; CELL GROWTH; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DNA DEGRADATION; DRUG CYTOTOXICITY; ENZYME DEGRADATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0034107048     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.1999.1131     Document Type: Article

References (51)

1. Altman RD, Johnston CC, Khairi MRA, Wellman H, Serafini AN and Sankey RR (1973) Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). N Engl J Med 289: 1379-1384
2. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J and Knight RD (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334: 488-493
3. Boonecamp PM, van der Wee-Pais LJA, van Wijk-van Lennep MML, Thesing CW and Bijvoet OL (1986) Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. J Bone Miner Res 1: 27-39
4. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G and Thomson CB (1993) bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74: 597-608
5. Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD and Clezardin P (1997) Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 57: 3890-3894
6. Bossy-Wetzel E, Newmeyer DD and Green DR (1998) Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. EMBO J 17: 37-49
7. Boyde A, Maconnachie E, Reid SA, Delling G and Mundy GR (1986) Scanning electron microscopy in bone pathology: review of methods. Potential and applications. Scanning Electron Microsc IV: 1537-1554
8. Bradford M (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein dye binding. Analyt Biochem 72: 248-254
9. Busch M, Rave-Frank M, Hille A and Duhmke E (1998) Influence of clodronate on breast cancer cells in vitro. Eur J Med Res 3: 427-431
10. Cardone MH, Roy N, Stennicke NR, Salvesen GS, Franke TF, Stanbridge E, Frisch S and Reed JC (1998) regulation of cell death protease caspase-9 by phosphorylation. Science 282: 1318-1321
11. Cory AH, Owen TC, Barltrop JA and Cory JG (1991) Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 3: 207-212
12. Coxen FP, Benford HL, Russell RGG and Rogers MJ (1998) Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs. Mol Pharmacol 54: 631-638
13. Dbaibo GS, Perry DK, Gamard CJ, Platt R, Poirier GG, Obeid LM and Hannun YA (1997) Cytokine response modifier a (CrmA) inhibits ceramide formation in response to tumor necrosis factor (TNF)-α: crmA and Bcl-2 target distinct components in the apoptotic pathway. J Exp Med 185: 481-490
14. Diel IJ, Solomayer E, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M and Bastert G (1998) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339: 357-363
15. Duke RC and Cohen JJ (1992) Morphological, biochemical, and flow cytometric assays of apoptosis. In: Current Protocols in Immunology (suppl. 3) Coligan JE, Kruisbeck AM, Margulies DH, Shevach EM and Strober W (eds) pp. 3.17.1-3.17.16. Green/Wiley: New York
16. Fleisch H (1997) Bisphosphonates in bone disease, 3rd edn. Parthenon Publishing Group: New York
17. Frith JC, Monkkonen J, Blackburn GM, Russell RGG and Rojers M (1997) Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(β,γ-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 12: 1358-1367
18. Golstein P (1997) Controlling cell death. Science 275: 1081-1082
19. Hall DG and Stoica G (1994) Effects of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system. J Bone Miner Res 9: 221-230
20. Hortobagyi GN, Theriault RL, Lipton A Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight RD, Heffernan M, Mellars K and Reitsma DJ. (1998) Long term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 16: 2038-2044
21. Hughes DE, MacDonald BR, Russell RGG, and Gowen M (1989) Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 83: 1930-1935
22. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR and Boyce BF (1995) Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10: 1478-1487
23. Kanis JA, Urwin GH, Gray RE, Beneton MN, McCloskey EV, Hamdy NA and Murray SA (1987) Effects of intravenous etidronate on skeletal and calcium metabolism. Am J Med 82: 55-70
24. Kanis JA, Powles T, Paterson AHG, McCloskey EV and Ashley S (1996) Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 19: 663-667
25. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE and Poirier GG (1993) Specific proteolytic cleavage of poly (ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 53: 3976-3985
26. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG and Earnshaw WC (1994) Cleavage of poly (ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371: 346-347
27. Lin JH, Duggan DE, Chen IW and Ellsworth RL (1991) Physiological disposition of alendronate, a potent antiosteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos 19: 926-932
28. Lowik CWGM, van der Pluijm G, van der Wee-Pals LJA, Bloys van Treslong-de Groot H and Bijvoel OLM (1988) Migration and phenotypic transformation of osteoclast precursors into mature osteoclast the effect of a bisphosphonate. J Bone Miner Res 3: 185-192
29. Luckman SP, Coxon FP, Ebetino FH, Russell RGG and Rojers MJ (1998) Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 13: 1668-1678
30. Marzo I, Susin SA, Petit PX, Ravagnan L, Brenner C, Larochette N, Zamazmi N and Kroemer G (1998) Caspases disrupt mitochondrial membrane barrier function. FEBS Lett 427: 198-202
31. McConkey DJ and Orrenius S (1996) Signal transduction pathways in apoptosis. Stem Cells 14: 619-631
32. Mundy GR and Yoneda T (1998) Bisphosphonates as anticancer drugs. N Engl J Med 339: 398-400
33. Oltvai ZN, Milliman CL and Korsmeyer SJ (1993) Bcl-2 heterodimerises in vivo with a conserved homologue, bax, that accelerates programmed cell death. Cell 80: 285-291
34. Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J and Ashley S (1993) Double-blinded controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11: 59-65
35. Plasmans CMT, Kuypers W and Slooff TJJH (1978) The effect of ethanal-hydroxy-1,1-diphosphonic acid (EHDP) on matrix induced ectopic bone formation. Clin Orthop 132: 233-243
36. Powell GJ, Southby J, Danks JA, Stillwell RG, Hayman JA, Henderson MA, Bennett RC and Martin TJ (1991) Localisation of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res 51: 3059-3061
37. Powles TJ, Paterson AHG and Nevantaus A (1998) Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer. Prog Proc Soc Clin Oncol 17: 123a
38. Reed J (1994) bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1-6
39. Ryzen E, Martodam R, Troxell M, Benson A, Paterson A, Shepard K and Hicks R (1985) Intravenous etidronate in the management of malignant hypercalcaemia. Arch Intern Med 145: 449-452
40. Sasaki A, Boyse BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR and Yoneda T (1995) Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55: 3551-3557
41. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E and Rodan GA (1991) Bisphosphonates action. Alendronate localization in rat bone and effects on osteoclast ultrastructure J Clin Invest 88: 2095-2105
42. Selander KS, Monkkonen, Karhukorpi E, Harkonen P, Hannuniemi R and Vaananen KK (1996) Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 50: 1127-1138
43. Shipman CM, Rojers MJ, Apperley JF, Russell RGG and Croucher PI (1997) Bisphosphonates induce apoptosis in human myeloma cell lines: a novel antitumour activity. Br J Haematol 98: 665-672
44. Shipman CM, Croucher PI, Russell RGG, Helfrich MH and Rogers MJ (1998) The bisphosphonates incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the Mevalonate pathway. Cancer Res 58: 5294-5297
45. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS and Dixit VM (1995) Yama/CPP32β, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 80: 801-809
46. v integrin antisense oligodeoxynucleotides induce detachment and apoptosis of osteoclast and breast carcinoma cell. Proceedings from the 19th Annual Meeting of the American Society for Bone Miner Research S252
47. Van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Lowik C and Papapoulos S (1996) Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98: 698-704
48. Vitale M, Matola TD, Rossi G, Laezza C, Fenzi G and Bifulco M (1999) Prenyltransferase inhibitors induce apoptosis in proliferating thyroid cells through a p53-independent, CrmA-sensitive, and caspase-3-like protease-dependent mechanism. Endo 140: 698-704
49. Wingen F, Eichmann T, Manegold C and Krempien B (1986) Effects of new bisphosphonic acids on tumor-induced bone destruction in the rat. J Cancer Res Clin Oncol 111: 35-41
50. Wosikowski K, Kung W, Hasmann M, Loser R and Eppenberger U (1993) Inhibition of growth-factor-activated proliferation by anti-oestrogen and effects of on early gene expression of MCF-7 cells. Int J Cancer 53: 290-297
51. Wyllie AH (1980) Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 284: 555-556